Jiangping Yang
State Key Laboratory Of Biotherapy And Cancer Center
Chengdu, China
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
CAR-T cell engineered with TCR-like antibody specific for HBV surface antigen epitope E183-91/HLA-A *0201 exhibit potent activity against HBV-HCC.
Journal: Oncoimmunology
Published: August 18, 2025
Recurrent Patterns in Patients With Nasopharyngeal Caricinoma and Risks Leading to Inaccurate Delineation in Marginal Failure in the Era of Intensity-Modulated Radiotherapy.
Journal: Head & neck
Published: August 21, 2024
Optimization of collimator angle combined island blocking with parked gap achieves superior normal tissue sparing in SBRT planning of multiple liver lesions.
Journal: Journal of applied clinical medical physics
Published: August 18, 2023
Dosimetric comparison in sparing normal tissue dosage by using auto-SBRT planning in oligo liver tumors.
Journal: Frontiers in oncology
Published: August 05, 2023
Chimeric antigen receptor engineered natural killer cells for cancer therapy.
Journal: Experimental hematology & oncology
Published: July 01, 2023
Advancements of radiotherapy for recurrent head and neck cancer in modern era.
Journal: Radiation oncology (London, England)
Published: May 17, 2023
Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer.
Journal: Therapeutic advances in medical oncology
Published: October 04, 2022
Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
Journal: Frontiers in pharmacology
Published: April 20, 2022
m6A Regulators Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization In Nasopharyngeal Carcinoma.
Journal: Frontiers in immunology
Published: August 21, 2021
A novel dosimetric metrics-based risk model to predict local recurrence in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
Journal: Radiation oncology (London, England)
Published: July 12, 2021
Case Report: High-Level MET Amplification as a Resistance Mechanism of ROS1-Tyrosine Kinase Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer.
Journal: Frontiers in oncology
Published: December 22, 2020
Last Updated: 09/26/2026